No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
www.seegene.comNo one on the platform currently holds 096530.KQ.
No tracked institution reports a position in 096530.KQ as of their last filing.
No one on the platform has traded 096530.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.2% | — | — | — | ||
| Rev. Growth % | 14.5% | -15.9% | ||||
| Profit Margin % | 10.2% | 13.2% | 15.6% | |||
| Free Cash Flow Margin % | 23.6% | 19.9% | 16.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $547.7B | +15.0% | $1949.00 | $1941.47–$1956.53 | — | 2 |
| 2027 | $603.8B | +10.2% | $1807.00 | $1642.89–$1971.11 | — | 2 |
| 2028 | $670.0B | +11.0% | $2043.00 | $2003.80–$2082.20 | — | 1 |
| 2029 | $853.0B | +27.3% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.13% |
| $735.4B |
| — |
| 137310.KSSD BioSensor, Inc | $6190.00 | -0.32% | $740.4B | — |
| 185750.KSChong Kun Dang Pharmaceutical Corp. | $65900.00 | -0.90% | $868.3B | — |
Source: Financial Modeling Prep · peers by sector/industry